OCT Assessment of VLST
OCT (VLST, n=6; L-ISR, n=32). The mean period between DES implantation and OCT follow-up was 37±17 months. We identified 20 consecutive risk-factor-balanced control patients without any evidence of thrombosis or restenosis who underwent angiographic and OCT follow-up >1 year after DES implantation (mean period, 38±19 months). All of them gave consent for OCT.
All patients were medicated with aspirin 100 mg/day. Additionally, ticlopidine 200 mg/day or clopidogrel 75 mg/day were continued for at least 3 months after sirolimus-eluting stent implantation or for 6 months after paclitaxel-eluting stent implantation.
Patients were excluded if they had congestive heart failure or hemodynamic instability caused by acute myocardial infarction. In addition, patients with left main disease, with bifurcation lesions of the left anterior descending artery and the left circumflex artery or ostial lesions of the right coronary artery were excluded because of the expected difficulty in inserting the occlusion balloon. Moreover, patients with extremely tortuous vessels or with heavily calcified lesions were excluded because the advancement of the OCT catheter was not considered possible. This study was approved by the Tokushima Red Cross Hospital Ethics Committee, and all study patients gave informed consent before the catheterization procedure.
Quantitative Coronary Angiographic Analysis
Quantitative angiographic parameters were analyzed for the target lesion using dedicated software (QCA-CMS 5.1; Medis Imaging Systems, Leiden, the Netherlands). ISR was defined as >50% diameter stenosis in the vessel segment within a stent on angiography.
Definition of VLST and L-ISR
Definite stent thrombosis was diagnosed according to the Academic Research Consortium as angiographic evidence of thrombus (or total occlusion) in association with clinical findings of acute coronary syndrome. The angiographic evidence of non-occlusive thrombus was defined as a spherical, ovoid, or irregular, non-calcified filling defect or lucency surrounded by contrast material seen in multiple projections, or persistence of contrast material within the lumen, or a visible embolization of intraluminal material downstream. 7 A lesion that was identified as a non-occlusive thrombus even if it was associated with >50% diameter stenosis in the vessel segment within a stent on angiography was regarded as a stent thrombosis. VLST was defined as definite stent thrombosis occurring >1 year after DES implantation. L-ISR was defined as ISR occurring in the previously implanted DES segment, seen on angiography, due to recurrent ischemia >1 year after DES implantation.
OCT and Analysis
The occlusion technique was adopted to completely remove blood from the artery. A 0.016-in (0.4 mm) OCT catheter (Image Wire, LightLab Imaging, Westford, MA, USA) was advanced to the distal end of the stented segment through a 3-F occlusion balloon catheter (Helios, LightLab Imaging). The occlusion balloon was inflated to low pressure (40.5-70.9 kPa) at the proximal site of the stented segment with simultaneous infusion of lactated Ringer's solution at 0.5-1.0 ml/s from the distal tip of the occlusion balloon. The entire length of the stent was imaged with automated pullback at 1.5 mm/s (frame rate, 20 frames/s).
OCT images were evaluated by 2 independent observers who were blinded to the clinical presentations. If there was discordance between the observers, a consensus opinion was reached by discussion or a third observer judged the images. Strut-level qualitative OCT analysis was performed for each individual strut every 13 or 14 frames (ie, every 1.0 mm) along the entire stented segment. We excluded the frames including the ostium of side branches. Also, the frames including intimal hyperplasia >50% of stent area and the struts behind a massive thrombus were excluded from the analysis because the limited penetration depth of OCT images and signal attenuation due to lipid pools or thrombus resulted in interruption of the evaluation of the strut condition below the intima. Stent struts 
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were classified into 5 categories: covered embedded; covered protruding; covered malapposed; uncovered apposed; and uncovered malapposed (Figure 1) . The uncovered struts are those in which the endoluminal surface of the struts is not visibly covered with a tissue layer. The malapposed struts are defined as those in which the distance from the endoluminal surface of the strut to the lumen contour is greater than the sum of the metal and polymer thickness (sirolimus-eluting stent, 160 μm; paclitaxel-eluting stent, 130 μm). 8 The covered embedded struts are covered by tissue and do not interfere with the lumen contour. The covered protruding struts are covered by tissue and interfere with the lumen contour. The malapposed struts include both covered and uncovered struts. The number of each kind of strut was counted for each frame. Similarly, the total number of frames with uncovered or malapposed struts was counted for each stented segment. The proportion of overall uncovered struts or uncovered malapposed struts was calculated as the number of those struts divided by the total number of struts for each stented segment. The proportion of frames with at least 1 uncovered strut or malapposed strut per total number of frames for each stented segment was also calculated. The tissue characteristics within the stent were assessed using the validated OCT criteria. 9,10 A thrombus was defined as an irregular mass protruding into the lumen (>250 μm at its thickest point). Lipid pools appeared as diffusely bordered, signal-poor regions with overlying signalrich bands. Lipid-laden-like neointima was defined as neointima including lipid pools within the stent. Neointimal disruption was a ruptured fibrous cup that connected the lumen with the underling lipid pools within the stent.
Statistical Analysis
All categorical variables were compared using the chi-square method or Fisher's exact test. All results of continuous variables are expressed as mean ± SD. The comparisons of continuous variables between groups were performed using unpaired t-test and analysis of variance (ANOVA) with the Bonferroni post-hoc test. Statistical significance was set at P<0.05 for all Data given as mean ± SD or n (%). VLST, very late stent thrombosis; L-ISR, late in-stent restenosis; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent. Figure 2 . Proportion of patients/frames/struts that are uncovered or malapposed. Patient, patients with at least 1 uncovered or malapposed strut/total number of patients; frame, frames with at least 1 uncovered or malapposed strut/total number of frames for each stented segment; strut, number of uncovered or malapposed struts/total number of struts for each stented segment.
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analyses except for post-hoc analysis, in which significance was set at P<0.017 (0.05 divided by 3). All analyses were performed using SPSS 11.0 (SPSS, Chicago, IL, USA).
Results
Baseline Characteristics and Clinical Presentation
There were no significant differences in baseline clinical and angiographic characteristics among the VLST, L-ISR, and no-event groups ( Table 1) . The most frequently used stent type was the sirolimus-eluting stent in all groups. Off-label uses such as acute coronary syndrome, bifurcation lesions, and chronic total occlusion were also similar among the 3 groups. The quantitative coronary angiographic parameters did not differ significantly among the 3 groups. Of the 6 patients with angiographically confirmed stent thrombosis (5 sirolimus-eluting stent and 1 paclitaxel-eluting stent), 4 patients had an occlusive thrombus in the stented seg- Optical coherence tomography images: (A) several white thrombi ( * ) and many uncovered struts (arrows) were found at the distal edge of the stent; (B) many uncovered struts (arrows) and a malapposed strut (arrowhead) were found at the mid-portion of the stent; (C,D) white and red thrombi ( * ) were found at the proximal site of the stent. Table 1 . OCT Assessment of VLST ment, whereas 2 patients had a non-occlusive thrombus in the stented segment. The former patients required thrombectomy and/or balloon angioplasty before OCT in order to restore the coronary flow. The mean period between DES implantation and occurrence of VLST was 36.0±9.4 months. On admission, all patients with VLST were taking only aspirin 100 mg/day, not ticlopidine or clopidogrel. Of the 32 patients in the L-ISR group, 4 patients (13%) presented clinically with unstable angina. The mean period between DES implantation and OCT was similar among the 3 groups.
OCT Findings
The OCT findings are given in Figure 2 ). The proportion of malapposed struts per total number of struts for each stented segment was significantly higher in the VLST group than in the no-event group (7.3±8.7% vs. 1.1±2.4%, P=0.01). The proportion of frames with at least 1 malapposed strut per total frames for each stented segment was also significantly higher in the VLST group than in the no-event group (24.6±21.2% vs. 3.8±6.3%, P=0.001; Table 2; Figure 2) . A summary of all VLST cases is given in Table 3 (representative cases are shown in Figures 3,4) . Of the 6 patients, 4 had higher overall rates of uncovered struts and malapposed struts, whereas patients 3 ( Figure 4 ) and 6 had lower overall rates of uncovered struts and malapposed struts. These 2 patients had finding of lipid-laden-like neointima with disruption and adjacent thrombus. Lipid-laden-like neointima with disruption was also observed in 11 patients (34%) in the L-ISR group. All 4 patients with unstable angina in the L-ISR group were also found to have lipid-laden-like neointima with disruption and intracoronary thrombus.
Discussion
A previous intravascular ultrasound study found that mechan- 
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ical factors such as stent underexpansion are important in early thrombosis after DES implantation. 11 In contrast, previous reports have also shown that biologic factors such as chronic inflammation, hypersensitivity, delayed artery healing, and malapposition due to positive artery remodeling are more important in late thrombosis, especially very late thrombosis after DES implantation. 12-14 These reports were based on pathological findings from autopsy. The main findings of the present study are as follows: (1) the DES-treated lesions that develop very late thrombosis had a higher number of uncovered and incompletely apposed struts on OCT; and (2) that these conditions alone cannot explain all events of very late thrombosis after DES implantation, and that presence of a lipid-laden-like neointima with disruption may be another possible mechanism. A recent study produced similar OCT results for VLST after DES implantation, 15 but in the present study the significance of uncovered and malapposed struts in the VLST group was analyzed with regard to quantitative strut level analysis and by comparison with an L-ISR and no-event groups. To our knowledge, the present study is the first to use in vivo OCT showing the significance of delayed neointimal coverage and incomplete stent apposition in DES-treated lesions that developed very late thrombotic clinical events, using quantitative strut level analysis.
Strut Coverage and Stent Apposition
The measurement of tiny layers of tissue covering the stent struts became possible because the microenvironment of the struts on the luminal side can be clearly seen on high-resolution OCT. 16 In the present study, the overall proportion of uncovered struts was 7.6% for the control subjects, in agreement with other OCT studies reporting strut coverage after DES implantation. 17, 18 The proportion of uncovered struts was significantly higher in DES that developed thrombosis compared with those that developed restenosis and those that did not have such events. The present findings are in agreement with previous pathological studies showing delayed endothelial coverage on the stent struts in late DES thrombosis.
3-5
Although it is generally accepted that most cases of incomplete stent apposition are not associated with clinical adverse cardiovascular events, 19,20 intravascular ultrasound of late DES thrombosis often shows incomplete stent apposition at the time of the event. 21, 22 Furthermore, a previous pathological study suggested that malapposition/incomplete stent apposition is an additional risk factor for late DES thrombosis. 4, 5 The present study has found that the frequency of malapposed struts was significantly higher in DES that developed thrombosis compared with those that did not develop such an event. The mechanism of incomplete stent apposition due to positive remodeling is thought to be related to cytostatic effects of sirolimus on neointimal formation, 19,20 and localized hypersensitivity to the polymer coating. 12 A significant gap between struts and vessel wall or aneurysm formation might reduce local blood flow that promotes platelet adhesion and coagulation cascade. 23 The potential clinical consequences of malapposition/incomplete stent apposition, however, remain controversial because many of these struts persist for years without leading to VLST, and some previous studies have demonstrated that malapposition/incomplete stent apposition may be considered only an intravascular ultrasound finding without any implications of clinical adverse events. 19, 20 Further larger studies are required to determine the potential clinical significance.
Additionally, in a recent study coronary artery aneurysms were identified in 1.7% of patients after DES implantation on follow-up angiography. Of these patients, 14.3% presented with VLST. 24 In another recent study, peri-stent contrast staining, defined as contrast staining outside the stent contour extending to >20% of the stent diameter, was observed in 2.5% of patients after sirolimus-eluting stent implantation on follow-up angiography, and was associated with VLST. 25 Nakagawa concluded that coronary artery aneurysms occur in extreme cases of vessel wall destruction, and relatively milder inflammatory changes are recognized as peri-stent contrast staining on angiography and as late-acquired incomplete stent apposition on intravascular ultrasound or OCT. 26 In the present study, neither coronary artery aneurysm nor peri-stent contrast staining as an angiographic finding were observed in any of the cases of VLST.
The cause of late DES thrombosis is likely multifactorial. Although delayed arterial healing is the primary reason underlying cases of late DES thrombosis, the combination of several additional procedural and/or clinical risk factors such as malapposition, bifurcation stenting, excessive stent length, penetration of necrotic core, local arterial hypersensitivity, and withdrawal of antiplatelet therapy plays an important role. 4,5,13,27
Atherosclerotic Change in DES
In the present study, 2 cases of VLST involved the OCT findings of increased signal intensity and marked signal attenuation that indicate lipid-laden-like neointima, even though the frequency of uncovered and malapposed struts was low.
Nakazawa et al reported that after 4 months an atherosclerotic change consisting of lipid-laden foamy macrophage infiltrates within the neointima was observed within the stent; moreover, necrotic core formation was found to have occurred at 9 months after DES implantation in autopsy cases. These processes were seen to progress more rapidly after DES implantation than after bare-metal stent (BMS) implantation (>2 years in BMS). The underling atherosclerotic lesions may progress due to endothelial dysfunction that allows accelerated infiltration of lipid after DES implantation. 28 An angioscopy study suggested that the yellow neointima representing newly formed atherosclerotic neointima in DES may contribute more to thrombus formation than poor stent coverage. 29 In the previous OCT studies of extended late-phase thrombosis after BMS implantation, several patients with lipid-rich plaques within the BMS had intimal disruption and thrombus formation; moreover, this condition is clinically indicative of acute coronary syndrome. These studies indicate that this phenomenon may be a possible mechanism for very late thrombosis because the formation of lipid-laden-like neointima is closely correlated with new atherosclerotic progression and tissue instability due to intimal disruption and thrombus formation. 30, 31 An intravascular ultrasound study showed that 43.5% of DES-treated patients with VLST had neoatherosclerotic plaque and plaque rupture within stents. 32 Although the timing of atherosclerotic change after DES implantation is obviously different from that after BMS implantation, a similar phenomenon may occur within the DES that may eventually progress to very late thrombosis. The present results suggest that there may be other possible mechanisms of late DES thrombosis that are not related to delayed healing or malapposition.
Interestingly, a recent clinical study showed that, on OCT, in-stent neoatherosclerosis and intimal ruptures were frequent in DES-treated patients with ISR. 33 The present study also showed that there was lipid-laden-like neointima involved in several cases of L-ISR. Moreover, 36% of patients (4/11) with lipid-laden-like neointima with disruption presented clinically OCT Assessment of VLST with unstable angina. This result indicates that progression of lipid-laden-like neointima may promote the disruption and the subsequent late thrombosis, and that these processes may be overlapping in part in cases of late restenosis or late thrombosis. Also, a previous pathological study demonstrated that ISR was an additional risk factor for late stent thrombosis. 5 Because the definition of stent thrombosis and ISR are based on the angiographic findings, acute coronary syndrome that involves total occlusion on angiography is regarded as definite stent thrombosis. Therefore, it is difficult to determine whether VLST is due to delayed arterial healing, or lipidladen-like neointima with disruption, or progression of ISR, or other factors. There is a possibility that stent thrombosis diagnosed according to the Academic Research Consortium includes a part of all ISR cases.
Study Limitations
First, the sample size of the VLST group was small because of the low incidence of VLST and the difficulty in conducting OCT in the VLST patients with hemodynamic instability. The issue of selection bias is also a limiting factor. Larger studies are necessary for a more precise evaluation of the mechanisms of late thrombosis and the differences between late restenosis and late thrombosis. Second, although OCT can be performed before percutaneous coronary intervention in the ISR patients, thrombectomy and/or balloon angioplasty is necessary to recanalize coronary flow in cases of VLST with occlusive thrombus. Therefore, the possibility exists that thrombus formation and neointimal rupture may have been caused mechanically by these procedures. In addition, the number of malapposed struts may be underestimated in these cases. Moreover, it is unclear whether a malapposed strut is late-acquired or has persisted from the initial DES implantation because OCT cannot be performed serially. Third, we could not analyze all of the struts for each stent because the frames including the ostium of side branches, those with intimal hyperplasia >50% of stent area, and the struts behind a massive thrombus were excluded for the reason noted previously. Fourth, we could not examine the different types of DES because there were not sufficient patients with each type of DES to allow a comparison, particularly in the VLST group.
Conclusions
Delayed neointimal coverage and incomplete stent apposition were frequently observed in the DES-treated lesions that developed very late thrombosis when compared with those that developed restenosis and those that did not develop such events. These observations, however, cannot explain all mechanisms of very late thrombosis after DES implantation. Lipidladen-like neointima with disruption within the DES may be another possible mechanism.
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